Back to Journals » Journal of Experimental Pharmacology » Volume 13

Binge Eating Disorder: A 5-Year Retrospective Study on Experimental Drugs

Authors Levitan MN, Papelbaum M, Carta MG, Appolinario JC, Nardi AE

Received 2 November 2020

Accepted for publication 11 January 2021

Published 29 January 2021 Volume 2021:13 Pages 33—47

DOI https://doi.org/10.2147/JEP.S255376

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Bal Lokeshwar


Michelle N Levitan,1,2 Marcelo Papelbaum,2 Mauro G Carta,3 Jose C Appolinario,1 Antonio E Nardi1

1Psychiatry Institute/Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; 2Eating Disorders Department/Sheba Medical Center, Ramat Gan, Israel; 3Dipartimento di Scienze Mediche e Sanità Pubblica, Università Degli Studi di Cagliari, Cagliari, Italy

Correspondence: Michelle N Levitan Email milevitan@gmail.com

Abstract: Binge eating disorder (BED) affects a significant rate of the general population causing a negative impact on their quality of life, weight, and self-esteem. Besides psychological treatments that compose the majority of the studies, pharmaceuticals have contributed to improve a host of clinical parameters, thus being an important component of the treatment. We opted to target the latest results by performing a review of the literature on the pharmacology for BED from the last 5 years. To achieve this goal, the terms: “binge eating disorder” and “treatment” were added to the PubMed database and the website clinicaltrials.gov. At least five drugs were either being tested or had already been recognized to improve BED symptoms – although only lisdexamfetamine is currently approved by the FDA to treat this condition. However, due to a better understanding of BED psychopathology in the last decade, it is notorious that improvement of eating-related symptoms is not the only desired target. Due to the significant comorbidity percentage (30%), weight loss is highly pursued, as well as the amelioration of clinical parameters which highlights the importance of having new agents combining both objectives.

Keywords: binge eating disorder, treatment, pharmacological treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]